Lone Star Agrees $3 Billion Deal for Lonza Ingredients Unit (1)

Lone Star Funds has agreed to acquire Lonza Group AG’s capsules and health ingredients business in a deal valued at 2.3 billion Swiss francs ($3 billion) including debt.

Lonza will receive 1.7 billion Swiss francs upfront and retain a 40% stake in the capsules and health ingredients unit, according to a statement Friday that confirmed a Bloomberg News report.

Basel-based Lonza is the world’s largest contract manufacturer of monoclonal antibodies, the technology behind a new class of Alzheimer’s drugs such as Eli Lilly & Co.’s donanemab.

The company’s Chief Executive Officer Wolfgang Wienand aims to make Lonza a ...